Experiment 638243
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Ginkgo biloba (GINKGOACEAE) |
| Citation | KIDD,PM:. (1999). A REVIEW OF NUTRIENTS AND BOTANICALS IN THE INTEGRATIVE MANAGEMENT OF COGNITIVE DYSFUNCTION.. 4(3) |
| Amount utilized | |
| Compound isolated | |
| Disease | IN CLINICAL TRIALS ONLY 29 PERCENT OF THEIR PATIENTS BENEFITED FROM 120 MG PER DAY OF GBE, TO AN EXTENT COMPARABLE TO A SIX-MONTH DELAY IN DISEASE PROGRESSION. ACCORDING TO THEIR ANALYSIS, THE SMALL PROPORTION OF PATIENTS WHO BENEFIT FROM GINKGO AND THE MINOR EXTENT OF BENEFIT ARE BOTH EXCEEDED BY HIGH DOSES (160 MG PER DAY) OF TACRINE, THE FIRST OF THE TWO PHARMACEUTICALS APPROVED FOR ALZHEIMER'S DISEASE. |
| Dose amount | 120.0 MG |
| Number | 3 |
| Qualitative result | INACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Extract | ETOH(100%)EXT |
| Gender | GIVEN TO BOTH SEXES |